Huntington National Bank Avadel Pharmaceuticals PLC Transaction History
Huntington National Bank
- $12.3 Billion
- Q1 2024
A detailed history of Huntington National Bank transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Huntington National Bank holds 1 shares of AVDL stock, worth $14. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1
Previous 1
-0.0%
Holding current value
$14
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AVDL
# of Institutions
133Shares Held
68.4MCall Options Held
1.01MPut Options Held
2.03M-
Janus Henderson Group PLC London, X012.9MShares$182 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$124 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$95 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$80.3 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$55.8 Million8.97% of portfolio
About AVADEL PHARMACEUTICALS PLC
- Ticker AVDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 60,581,300
- Market Cap $852M
- Description
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...